Quick answer: latest quarter results, by ticker or company name

Reported Q: Q1 2025 Rev YoY: -2.6% EPS YoY: -8.2% Move: -3.52%

Teladoc Health Inc

4LL.F

€4.00 -3.52%

Exchange FSX Sector Healthcare Industry Medical Healthcare Information Services

Q1 2025

Published: May 1, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 4LL.F

Reported

Report Date

May 1, 2025

Quarter Q1 2025

Revenue

629.37M

YoY: -2.6%

EPS

-0.53

YoY: -8.2%

Market Move

-3.52%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $629.37M down 2.6% year-over-year
EPS of $-0.53 decreased by 8.2% from previous year
Gross margin of 68.7%
Net income of -93.01M
"" -

4LL.F

Company 4LL.F

Period Q1 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 11, 2026

Executive Summary

Teladoc Health reported a mixed Q1 2025, underscoring the ongoing challenge of translating scale and platform breadth into recurring profitability while maintaining strong liquidity. Revenue totaled $629.4 million, down 2.6% year over year and 1.7% quarter over quarter, reflecting a normalization of utilization and payer mix dynamics in a competitive telehealth environment. Gross profit reached $432.5 million, delivering a robust gross margin of 68.7%, suggesting the core virtual care offerings maintain favorable margin characteristics even as the company absorbs higher operating costs.

Key Performance Indicators

Revenue

Decreasing

629.37M

QoQ: -1.74% | YoY: -2.59%

Gross Profit

Increasing

432.54M

68.73% margin

QoQ: -4.21% | YoY: 22.29%

Operating Income

Decreasing

-120.61M

QoQ: -150.15% | YoY: -56.48%

Net Income

Decreasing

-93.01M

QoQ: -92.14% | YoY: -13.58%

EPS

Decreasing

-0.53

QoQ: -89.29% | YoY: -8.16%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: $629.4M, YoY change -2.6%, QoQ change -1.7%; Gross Profit: $432.54M, Gross Margin ~68.7%, YoY +22.3%, QoQ -4.2%; Operating Income: -$120.61M, Operating Margin -19.16%, YoY -56.5%, QoQ -150.1%; Net Income: -$93.01M, Net Margin -14.78%, YoY -13.6%, QoQ -92.1%; EPS: -$0.53, YoY -8.16%, QoQ -89.29%; EBITDA: -$8.96M, EBITDA Margin -1.42%; Cash Flow: Operating Cash Flow $15.92M; Free Cash Flow $13.19M; Capex $-2.73M; Net Change in Cash -$105.0M; Cash and Cash Equivalents $1.19B; Total Debt $1.587B; Net Debt $393.44M; Current Ratio 1.68x; Quick Ratio 1.64x; Cash Ratio 1.25x; Revenue Mix Not Disclosed by Segment in the data; P/S 2.20x; P/BV ~0.97x; EV Multiple negative (-14.76x) due to substantial cash balance versus enterprise value.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	629.37M	-2.59%	-1.74%
Gross Profit	432.54M	22.29%	-4.21%
Operating Income	-120.61M	-56.48%	-150.15%
Net Income	-93.01M	-13.58%	-92.14%
EPS	-0.53	-8.16%	-89.29%

Key Financial Ratios

Gross Profit Margin

Excellent

68.70%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Weak

-0.19%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-0.15%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.03%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.07%

Return on equity suggests inefficient capital allocation

Current Ratio

Healthy

1.68

Current ratio shows adequate liquidity to meet short-term obligations

Debt to Equity

High Risk

1.11

Debt-to-equity indicates high leverage and elevated financial risk

P/E Ratio

Negative

-3.73x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

0.97x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q3 2025	626.44	-0.28	-2.2%	View
Q2 2025	631.90	-0.19	-1.6%	View
Q1 2025	629.37	-0.53	-2.6%	View
Q4 2024	640.49	-0.28	-3.0%	View
Q3 2024	640.51	-0.19	-3.0%	View

4LL.F

Teladoc Health Inc

Q3 2025 Report

Teladoc Health Inc (4LL.F) QQ3 2025 Results Analysis: Revenue Stabilizes at $626.4M; Margin Resilience Amid Opex Pressure...

Read full report

4LL.F

Teladoc Health Inc

Q2 2025 Report

Teladoc Health Inc (4LL.F) QQ2 2025 Results — Revenue Stability Amid Margin Pressure and Cash Flow Generation...

Read full report

4LL.F

Teladoc Health Inc

Q4 2024 Report

Teladoc Health Inc (4LL.F) QQ4 2024 Results — Revenue Flat at $640.5M with Narrow Losses, Strong Cash Position, and Improving Operating Leverage...

Read full report

4LL.F

Teladoc Health Inc

Q3 2024 Report

Teladoc Health Inc (4LL.F) QQ3 2024 Results — Stable Revenue, Margin Resilience, and Robust Cash Generation Amid Growth Investments...

Read full report

Teladoc Health Inc (4LL.F) Q1 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 4LL.F Quarterly Reports

4LL.F

4LL.F

4LL.F

4LL.F

Q1 2025 Reports in Healthcare Sector

307.F

Related Financial Data

Sector Analysis: Healthcare

4LL.F Full Profile

4LL.F Financial Statements

Earnings Calendar